Among the groups, the VV-iPDL1/GM-treated mice had maximal CD45+CD8+pentamer+ T cells in tumor infiltrates (Fig. 6d, e), indicative of VV-iPDL1/GM injections being most efficacious in activating neoepitope 4-specific T cells in the tumor-bearing mice. This evidence concerns the gene PTPRC and neoplasm.